Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine). Trastuzumab emtansine can be used for the research of advanced breast cancer^[1][2].

Trastuzumab emtansine (2 μg/mL; 3 d) significantly inhibits the proliferation of epithelial ovarian cancer (EOC) cells^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Trastuzumab emtansine (15 mg/kg; i.v. three to five times weekly for 3 weeks) exhibits significantly anti-tumor effect in mice^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

1018448-65-1

曲妥珠单抗-美坦新偶联物

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Verma S, et, al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012 Nov 8;367(19):1783-91.

  [2]. Menderes G, et, al. Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression. Gynecol Oncol. 2017 Oct;147(1):145-152.